United Therapeutics (UTHR) Stock Price, News & Analysis

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" UTHR shares.
View UTHR analyst ratings or view top-rated stocks.

10 equities research analysts have issued twelve-month target prices for United Therapeutics' stock. Their UTHR share price targets range from $215.00 to $330.00. On average, they anticipate the company's share price to reach $292.67 in the next year. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts.

United Therapeutics' stock was trading at $219.89 at the start of the year. Since then, UTHR shares have increased by 7.0% and is now trading at $235.31.
View the best growth stocks for 2024 here.

United Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 154.7% from the March 15th total of 1,920,000 shares. Based on an average daily volume of 431,700 shares, the days-to-cover ratio is presently 11.3 days. Currently, 11.3% of the company's shares are sold short.
View United Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our UTHR earnings forecast.

United Therapeutics Co. (NASDAQ:UTHR) issued its earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 EPS for the quarter, topping the consensus estimate of $4.28 by $0.08. The biotechnology company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. United Therapeutics had a net margin of 42.31% and a trailing twelve-month return on equity of 17.72%. The company's revenue was up 25.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.67 EPS.

ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Biotechnology & Genome ETF (PBE), Formidable Fortress ETF (KONG), Inspire Faithward Mid Cap Momentum ETF (GLRY), First Trust Health Care AlphaDEX Fund (FXH) and Alpha Intelligent - Large Cap Value ETF (AILV).

64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.19%), Atwood & Palmer Inc. (0.14%), New England Research & Management Inc. (0.02%), Cardinal Capital Management (0.02%), Alaska Permanent Fund Corp (0.02%) and Hennion & Walsh Asset Management Inc. (0.01%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek.
View institutional ownership trends.

Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.